<em>Decision-IQ:</em> When Is PCSK9 Inhibitor Therapy Beneficial?
Decision-IQ Decision-IQ

Decision-IQ: When Is PCSK9 Inhibitor Therapy Beneficial?


Maximum Credits:


Decision-IQ Decision-IQ


Maximum Credits:
Decision-IQ Decision-IQ


Maximum Credits:

Overview: This 15-minute educational activity highlights current evidence on the use of PCSK9 inhibitors in patients with dyslipidemia via critical case assessment that emulates the decision-making process during patient care visits. Links to useful resources are provided for a self-directed dive into recent data on patient- and disease-related factors important in selecting appropriate candidates for PCSK9 inhibitor therapy. In addition, strategies for optimizing individualized preventive therapy are reviewed.

CME Information:

Jennifer Robinson, MD, MPH
Professor, Departments of Medicine and Epidemiology
Director, Preventive Intervention Center
University of Iowa College of Public Health
Iowa City, IA
Activity Planners
Erin Grothey
Clinical Content Manager
Baltimore, MD

Laura Rafferty, ELS
Managing Editor
Baltimore, MD

Samantha Gordon
CME Specialist
Baltimore, MD
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Learning Objectives
Upon completion, participants should be able to:

  • Integrate evolving data and guideline recommendations into individualized treatment decisions for patients with dyslipidemia for whom PCSK9 inhibitor therapy may be appropriate

Target Audience
This activity is intended for cardiologists.
Series Overview/Statement of Need
The first PCSK9 inhibitors were approved in the summer of 2015, creating a significant change in the dyslipidemia treatment landscape. Despite a wealth of clinical data and practice recommendations from multiple professional associations, the identification of patients with atherosclerotic cardiovascular disease who are candidates for this treatment remains complex. Although recent prospective data support the clinical utility of PCSK9 inhibitors, many important unanswered questions remain related to the implications of long-term use and approaches for identifying optimal candidates for treatment. Thus, it is imperative that cardiologists receive updates on the management of dyslipidemia for optimal outcomes in this patient population.
Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: May 24, 2018
Expiration Date: May 23, 2019
Estimated Time to Complete This Activity: 15 minutes
Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
Jennifer Robinson, MD, MPH
Consulting fees/advisory boards: Amgen, Eli Lilly and Company, Merck & Co., Inc., Novo Nordisk, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc.
Contracted research: Acasti Pharma, Amarin, Amgen, AstraZeneca, Eisai Inc., Esperion, Merck & Co., Inc., Novo Nordisk, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi-aventis U.S. Inc., Takeda Pharmaceuticals North America, Inc.
The peer reviewers and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
Contact Information       
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or email info@med-iq.com.
Hardware/Software Requirements
Operating System
Microsoft Windows® 8, Windows 7
Mac OS 10.7 (Lion) or newer

Microsoft Internet Explorer 8.0 or later
Mozilla Firefox - latest version
Download: http://www.mozilla.org/en-US/firefox/new/
Google Chrome - latest version
Download: http://www.google.com/chrome
Apple Safari - latest version
Download: http://www.apple.com/safari/download/

PDF Viewer
Adobe Acrobat Reader® or Adobe Reader
Download: http://get.adobe.com/reader/

Adobe Flash Player
Adobe Flash Player 9 or later
Download: http://get.adobe.com/flashplayer/ 
For technical support, go to http://www.med-iq.com/index.cfm?fuseaction=content.support
ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Amgen.

© 2018 Med-IQ, Inc.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.